Combination comprising hdac inhibitor, ctla-4 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment
WO2019202001A1
Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment
TW202012395A
Pharmaceutical combination products comprising a histone deacetylase (hdac) inhibitor and a tlr7 agonist and/or tlr8 agonist for the treatment of cancer
SG11202008123VA
Combination comprising hdac inhibitor and cd137 agonist for cancer therapy
KR20200051712A
HDAC inhibitors in combination with immune checkpoint modulators for the treatment of cancer
TW201912183A
Hdac inhibitor in combination with antimetabolite agent for cancer therapy
KR20180130565A
Medical application of resminostat in Asian patients
WO2018184678A1
Hdac inhibitor in combination with vegf / vegfr interaction inhibitor for cancer therapy based on platelet count
WO2017060524A1
(e)-n-(2-aminophenyl)-3-(1-((4-(1-methyl-1h-pyrazol-4-yl)phenyl)sulfonyl)-1h-pyrrol-3-yl)acrylamide for the treatment of latent viral infections
WO2017013210A1
Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds
TW201639857A
Kv1.3 inhibitors and their medical application
TW201639843A
Kv1.3 inhibitors and their medical application
WO2014187894A1
Gene expression biomarkers and their use for diagnostic and prognostic application in patients potentially in need of hdac inhibitor treatment
AU2013283318A1
Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders
NZ605010A
Novel calcium salts of compound as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2011033094A1
Schedule of administration of benzazole derivatives in the treatment of leukemias
